

Orders received remained at the previous year's level and amounted close to EUR 5.0 billion and Comparable EBITA increased to EUR 619 million in 2023

Financial Statements Review 2023

February 7, 2024

Pasi Laine, President and CEO

Katri Hokkanen, CFO

Agenda

Financial Statements Review 2023

- 1 2023 in brief
- 2 Development of the segments and the business lines
- 3 Financial development
- 4 Dividend proposal, guidance and short-term market outlook




2023 in brief

2023 in brief

- Orders received remained at the previous year's level and amounted close to EUR 5.0 billion
- Net sales increased to EUR 5.5 billion
- Order backlog amounted close to EUR 4.0 billion
- Comparable EBITA increased to EUR 619 million and margin was 11.2%
- Gearing was 40%


Valmet in 2023

Orders received




- Services
- Automation
- Process Technologies

Net sales



- Services
- Automation
- Process Technologies

Comparable EBITA (excl. Other)




- Services
- Automation
- Process Technologies

| | | | | | |
|---|---------------------------------------|--|---|---|----------------------------|
| Orders received EUR 4,955 million | Net sales EUR 5,532 million | Comparable EBITA EUR 619 million | Comparable EBITA margin 11.2% | Order backlog EUR 3,973 million | Employees 19,160 |
|---|---------------------------------------|--|---|---|----------------------------|


Valmet's development since 2013

Orders received
(EUR billion)




Process Technologies segment
Services and Automation segments

Net sales
(EUR billion)




Process Technologies segment
Services and Automation segments

Comparable EBITA
(EUR million)



Comparable EBITA

Comparable EBITA margin
(%)




Comparable EBITA margin


2013 figures on carve-out basis.
2013–2020 figures have not been restated to reflect the new segment reporting structure which Valmet implemented as of January 1, 2022.

Orders received remained at the previous year's level and amounted to EUR 4,955 million in 2023

Orders received (EUR million)




Orders received in 2023 by Area (EUR million)



- Orders received increased in South America, remained at the previous year's level in North America and decreased in EMEA, China and Asia-Pacific in 2023 compared with 2022
 - South America, China and Asia-Pacific together accounted for 37% of orders received

Stable business orders received totaled EUR 3,100 million in 2023

Orders received (EUR million) in stable business




- Orders received in stable business were 262 million higher in 2023 compared with 2022
- Stable business represented 63% of Valmet's orders received in 2023 (34% in 2014)

2014–2020 figures have not been restated and 2015–2020 figures include internal orders received for the Automation Systems business line.


*Adjusted for acquisitions and foreign exchange rates (in calculating organic growth, 2023 orders received in euro translated by applying 2014 average exchange rates). Indicative only.

Order backlog EUR 3,973 million at the end of 2023

Order backlog (EUR million)



Structure of order backlog by segment



- Order backlog was EUR 430 million lower than at the end of 2022
- Approximately 85% of the order backlog is currently expected to be realized as net sales during 2024 (at the end of 2022, ~75% during 2023).
- Approximately 40% of the order backlog relates to stable business (~35% at the end of 2022)

Acquisitions in 2023

NovaTech Automation's Process Solutions business

- The acquisition strengthens Valmet's Automation segment with a reliable batch distributed control system (DCS)
- Net sales amounted to approximately USD 18 million in 2022 and the business operates in the United States and the Benelux countries
- Completed on January 3, 2023

Tissue Converting business from Körber


- Tissue Converting strengthens Valmet's Process Technologies and Services segments
- In 2023, net sales of the business amounted to EUR 296 million, of which EUR 76 million was booked to Valmet
- The business employs around 1,170 employees in Italy, Brazil, the U.S., China and Japan
- Completed on November 2, 2023

Process Gas Chromatography business of Siemens

- Process Gas Chromatography business will strengthen Valmet's Automation segment and process automation offering
- In 2022, net sales of the business amounted to approximately EUR 120 million and pro-forma adjusted EBITDA margin was approximately 10%
- The business employs around 300 people, and its main locations are in the USA, Germany, and Singapore
- Estimated to be completed on April 1, 2024 at the earliest

Demuth


- Demuth will strengthen Valmet's wood handling technology offering and services presence in South America
- Net sales of Demuth have been around EUR 20–30 million annually and the company employs around 300-400 people
- The acquisition is subject to relevant competition authority approvals and is estimated to be completed during the second or third quarter of 2024




Development of the segments and the business lines

Services: Orders received remained at the previous year's level at EUR 1,760 million in 2023


Orders received (EUR million)



Net sales (EUR million)



Comparable EBITA (EUR million and % of net sales)



- Orders received remained at the previous year's level compared with 2022
 - Orders received increased in South America, remained at the previous year's level in Asia-Pacific, China and EMEA and decreased in North America
 - Orders received increased in Pulp and Energy Solutions, remained at the previous year's level in Performance Parts, and Board, Paper and Tissue Solutions and decreased in Fabrics, and Rolls
- Net sales increased compared with 2022
- Comparable EBITA increased compared with 2022 due to higher net sales



Services segment in 2023


Orders received
EUR 1,760 million

Net sales
EUR 1,784 million


Employees
6,493

Market position
#1–2 Services


Orders received by customer segment



Orders received by area




Orders received by business




Automation: Orders received increased to EUR 1,340 million in 2023

Automation segment includes Automation Systems and starting from Q2/2022 also Flow Control


Orders received (EUR million)



Net sales (EUR million)



Comparable EBITA (EUR million and % of net sales)




- Orders received increased compared with 2022
- Net sales increased compared with 2022
- Comparable EBITA increased compared with 2022




Flow Control: Orders received amounted to EUR 789 million in 2023


Orders received (EUR million)*



Net sales (EUR million)*



- Orders received amounted to EUR 789 million in 2023
- Net sales amounted to EUR 777 million in 2023
- Integration of Flow Control into Valmet is completed and the targeted annual run rate synergies of EUR 25 million have been achieved



* 2016–2017 financials based on carve-out numbers; 2018–2019 financials based on Metso’s “Continuing operations” as in 2019 annual report; Q1/2020–Q1/2022 financials as reported in Neles’ Q1/2022 interim review.

Flow Control business line in 2023



Orders received
EUR 789 million

Net sales
EUR 777 million


Employees
2,841

Market position
#1 Pulp and Paper
#1–2 Industrial Gases
Top 10 Refining and
Chemicals



Orders received by customer industry



Orders received by area




Orders received by business




Automation Systems: Orders received increased to EUR 551 million in 2023


Orders received (EUR million)



Net sales (EUR million)



- Orders received increased compared with 2022
 - Orders received increased in North America, Asia-Pacific and China, remained at the previous year's level in EMEA and decreased in South America
 - Orders received increased in Energy and Process and remained at the previous year's level in Pulp and Paper
- Net sales increased compared with 2022



Automation Systems business line in 2023


Orders received
EUR 551 million

Net sales
EUR 551 million


Employees
2,330

Market position
#1–3 Pulp and Paper
#2–4 Energy and Process


Orders received by industry



Orders received by area




Orders received by product




Process Technologies: Orders received decreased to EUR 1,856 million in 2023


Orders received (EUR million)



Net sales (EUR million)



Comparable EBITA (EUR million and % of net sales)




- Orders received decreased compared with 2022
- Net sales remained at the previous year's level compared with 2022
- Comparable EBITA decreased compared with 2022 as the margins in some pulp projects were impacted by cost inflation and due to cost overruns in some tissue projects




Pulp and Energy business line: Orders received decreased to EUR 854 million in 2023

Orders received (EUR million)



Net sales (EUR million)



- Orders received decreased compared with 2022
 - Orders received increased in China and South America and decreased in EMEA, North America and Asia-Pacific
 - Orders received decreased in both Pulp and Energy
- Net sales remained at the previous year's level compared with 2022



Pulp and Energy business line in 2023

Orders received

EUR 854 million

Net sales

EUR 1,067 million

Employees


1,948

Market position

#2 Pulp


#1–3 Energy

Orders received by industry




■ Pulp
■ Energy

Orders received by area



■ North America
■ South America
■ EMEA
■ China
■ Asia-Pacific


Orders received by scope




■ Complete mills
■ Rebuilds
■ Single islands and products

Paper business line: Orders received decreased to EUR 1,002 million in 2023


Orders received (EUR million)



Net sales (EUR million)



- Orders received decreased compared with 2022
 - Orders received increased in South America, remained at the previous year's level in North America and decreased in EMEA, China and Asia-Pacific
 - Orders received increased in Small and Medium size Machines and in Tissue, and decreased in Stock Preparation and Recycled Fiber, and in Board and Paper
- Net sales remained at the previous year's level compared with 2022
- The fire at Rautpohja factory site in Finland in 2022 impacted Paper business line's operations during 2023



Paper business line in 2023

Orders received

EUR 1,002 million

Net sales

EUR 1,353 million

Employees

4,759


Market position

#1 Tissue


#1 Board

#1 Paper


Orders received by paper grade



Orders received by area




Orders received by scope



Valmet's development to a more stable company with more diversified industry exposure

Orders received (EUR million)



- Valmet's orders received from energy and other process industries amounted to over EUR 1.3 billion in 2023
- Since 2013 Valmet's orders received have grown organically and through acquisitions both in pulp and paper, and in energy and other process industries
- Valmet acquired Automation Systems in 2015 and the merger with Neles (Flow Control) was finalized in 2022
- EUR 744 million of the orders received in Energy and other process industries were from Automation segment in 2023



Financial development

Q4/2023 in brief

- Orders received decreased to close to EUR 1.2 billion
- Net sales remained at the previous year's level and amounted close to EUR 1.5 billion
- Order backlog amounted close to EUR 4.0 billion
- Comparable EBITA decreased to EUR 183 million and margin was 12.2%
- Gearing was 40%

Key figures

| EUR million | Q4/2023 | Q4/2022 | Change | 2023 | 2022 | Change |
|---|--------------|---------|---------|--------------|-------|--------|
| Orders received | 1,155 | 1,385 | -17% | 4,955 | 5,194 | -5% |
| Order backlog ¹ | 3,973 | 4,403 | -10% | 3,973 | 4,403 | -10% |
| Net sales | 1,499 | 1,540 | -3% | 5,532 | 5,074 | 9% |
| Comparable EBITA | 183 | 196 | -7% | 619 | 533 | 16% |
| % of net sales | 12.2% | 12.7% | -0.5 pp | 11.2% | 10.5% | 0.7 pp |
| EBITA | 172 | 190 | -9% | 605 | 550 | 10% |
| Operating profit (EBIT) | 148 | 156 | -5% | 507 | 436 | 16% |
| % of net sales | 9.9% | 10.1% | -0.3 pp | 9.2% | 8.6% | 0.6 pp |
| Adjusted earnings per share, EUR ² | 0.65 | 0.80 | -19% | 2.28 | 2.37 | -4% |
| Earnings per share, EUR | 0.56 | 0.66 | -15% | 1.94 | 1.92 | 1% |
| Comparable ROCE ³ | | | | 15% | 17% | -2 pp |
| Cash flow provided by operating activities | 123 | -13 | | 352 | 36 | >100% |
| Net debt to EBITDA ratio | | | | 1.46 | 0.78 | |
| Gearing ¹ | | | | 40% | 20% | 20 pp |

Items affecting comparability: EUR -10 million in Q4/2023 (EUR -6 million in Q4/2022) and EUR -14 million in 2023 (EUR 17 million in 2022).

1) At end of period

2) Adjusted earnings per share excludes the impact of fair value adjustments arising from business combinations, net of tax

3) Comparable return on capital employed (ROCE) before taxes

Services segment key figures

Q4 2023 in brief

| EUR million | Q4/2023 | Q4/2022 | Change |
|------------------|--------------|---------|---------|
| Orders received | 404 | 418 | -3% |
| Net sales | 508 | 505 | 1% |
| Comparable EBITA | 91 | 95 | -4% |
| % of net sales | 17.9% | 18.7% | -0.9 pp |

- Orders received remained at the previous year's level at EUR 404 million
 - Tissue Converting, which was integrated into Valmet in the beginning of November 2023, increased Services' orders received by EUR 21 million
 - Changes in FX rates decreased orders received by approximately EUR 14 million
- Net sales remained at the previous year's level
 - Tissue Converting increased Services' net sales by EUR 26 million
 - Changes in FX rates decreased net sales by approximately EUR 16 million
- Comparable EBITA remained at the previous year's level at EUR 91 million and margin decreased to 17.9%

Year 2023 in brief

| EUR million | 2023 | 2022 | Change |
|------------------|--------------|-------|--------|
| Orders received | 1,760 | 1,756 | 0% |
| Net sales | 1,784 | 1,606 | 11% |
| Comparable EBITA | 312 | 237 | 32% |
| % of net sales | 17.5% | 14.8% | 2.7 pp |

- Orders received remained at the previous year's level at EUR 1,760 million
 - Changes in FX rates decreased orders received by approximately EUR 53 million
- Net sales increased to EUR 1,784 million
 - Changes in FX rates decreased net sales by approximately EUR 49 million
- Comparable EBITA increased to EUR 312 million and the margin to 17.5%
 - Comparable EBITA increased due to higher net sales

Automation segment key figures

Q4 2023 in brief

| EUR million | Q4/2023 | Q4/2022 | Change |
|------------------|--------------|---------|---------|
| Orders received | 319 | 324 | -1% |
| Net sales | 375 | 363 | 3% |
| Comparable EBITA | 79 | 78 | 2% |
| % of net sales | 21.1% | 21.4% | -0.3 pp |

- Orders received remained at the previous year's level at EUR 319 million
 - Changes in FX rates decreased orders received by approximately EUR 12 million.
- Net sales remained at the previous year's level
 - Changes in FX rates decreased net sales by approximately EUR 11 million
- Comparable EBITA remained at the previous year's level at EUR 79 million and the margin was 21.1%

Year 2023 in brief

| EUR million | 2023 | 2022 | Change |
|------------------|--------------|-------|--------|
| Orders received | 1,340 | 1,081 | 24% |
| Net sales | 1,328 | 1,040 | 28% |
| Comparable EBITA | 248 | 190 | 30% |
| % of net sales | 18.6% | 18.3% | 0.4 pp |

- Orders received increased to EUR 1,340 million
 - Orders received of Flow Control, which was integrated into Valmet on April 1, 2022, amounted to EUR 217 million in Q1/2023
 - Changes in FX rates decreased orders received by approximately EUR 32 million
- Net sales increased to EUR 1,328 million
 - Changes in FX rates decreased net sales by approximately EUR 29 million
- Comparable EBITA increased to EUR 248 million and the margin was 18.6%

Process Technologies segment key figures

Q4 2023 in brief

| EUR million | Q4/2023 | Q4/2022 | Change |
|------------------|-------------|---------|---------|
| Orders received | 432 | 644 | -33% |
| Net sales | 615 | 672 | -8% |
| Comparable EBITA | 25 | 38 | -33% |
| % of net sales | 4.1% | 5.6% | -1.5 pp |

- Orders received decreased to EUR 432 million
 - Tissue Converting, which was integrated into Valmet in the beginning of November 2023, increased Process Technologies' orders received by EUR 40 million
 - Changes in FX rates decreased orders received by approximately EUR 19 million.
- Net sales decreased to EUR 615 million
 - Tissue Converting increased net sales by EUR 50 million
 - Changes in FX rates decreased net sales by approximately EUR 10 million
- Comparable EBITA decreased to EUR 25 million and the margin to 4.1%
 - Comparable EBITA decreased as the margins in some pulp projects were impacted by cost inflation and due to cost overruns in some tissue projects

Year 2023 in brief

| EUR million | 2023 | 2022 | Change |
|------------------|--------------|-------|---------|
| Orders received | 1,856 | 2,356 | -21% |
| Net sales | 2,420 | 2,428 | 0% |
| Comparable EBITA | 110 | 145 | -24% |
| % of net sales | 4.5% | 6.0% | -1.4 pp |

- Orders received decreased to EUR 1,856 million
 - Changes in FX rates decreased orders received by approximately EUR 53 million
- Net sales remained at the previous year's level
 - Changes in FX rates decreased net sales by approximately EUR 55 million
- Comparable EBITA decreased to EUR 110 million and the margin to 4.5%
 - Comparable EBITA decreased as the margins in some pulp projects were impacted by cost inflation and due to cost overruns in some tissue projects

Segment key figures

| Orders received, EUR million | Q4/2023 | Q4/2022 | Change | 2023 | 2022 | Change |
|------------------------------|---------|---------|--------|-------|-------|--------|
| Services | 404 | 418 | -3% | 1,760 | 1,756 | 0% |
| Automation | 319 | 324 | -1% | 1,340 | 1,081 | 24% |
| Process Technologies | 432 | 644 | -33% | 1,856 | 2,356 | -21% |
| Total | 1,155 | 1,385 | -17% | 4,955 | 5,194 | -5% |


| Net sales, EUR million | Q4/2023 | Q4/2022 | Change | 2023 | 2022 | Change |
|------------------------|---------|---------|--------|-------|-------|--------|
| Services | 508 | 505 | 1% | 1,784 | 1,606 | 11% |
| Automation | 375 | 363 | 3% | 1,328 | 1,040 | 28% |
| Process Technologies | 615 | 672 | -8% | 2,420 | 2,428 | 0% |
| Total | 1,499 | 1,540 | -3% | 5,532 | 5,074 | 9% |

| Comparable EBITA, EUR million | Q4/2023 | Q4/2022 | Change | 2023 | 2022 | Change |
|-------------------------------|---------|---------|--------|------|------|--------|
| Services | 91 | 95 | -4% | 312 | 237 | 32% |
| Automation | 79 | 78 | 2% | 248 | 190 | 30% |
| Process Technologies | 25 | 38 | -33% | 110 | 145 | -24% |
| Other | -13 | -14 | -10% | -50 | -39 | 29% |
| Total | 183 | 196 | -7% | 619 | 533 | 16% |


| Comparable EBITA margin, % of net sales | Q4/2023 | Q4/2022 | Change | 2023 | 2022 | Change |
|---|---------|---------|---------|-------|-------|---------|
| Services | 17.9% | 18.7% | -0.9 pp | 17.5% | 14.8% | 2.7 pp |
| Automation | 21.1% | 21.4% | -0.3 pp | 18.6% | 18.3% | 0.4 pp |
| Process Technologies | 4.1% | 5.6% | -1.5 pp | 4.5% | 6.0% | -1.4 pp |
| Total | 12.2% | 12.7% | -0.5 pp | 11.2% | 10.5% | 0.7 pp |

Comparable gross profit and SG&A expenses development

Comparable gross profit
(EUR million and % of net sales)




Comparable SG&A expenses
(EUR million and % of net sales)




- Comparable gross profit was 26.4% of net sales in Q4/2023 (25.6% in Q4/2022)
 - Stable business represented 59% of net sales (56% in Q4/2022)
- Comparable SG&A expenses were EUR 7 million higher in Q4/2023 compared with Q4/2022
 - Comparable SG&A expenses were 16% of net sales in Q4/2023 (15% in Q4/2022)

Cash flow provided by operating activities and net working capital

Cash flow provided by operating activities (EUR million)



Net working capital and orders received (EUR million)



- Cash flow provided by operating activities amounted to EUR 352 million in 2023 and EUR 123 million in Q4/2023
- CAPEX¹ amounted to EUR 125 million in 2023 and EUR 36 million in Q4/2023
- Net working capital amounted to EUR 191 million, which equals 4% of orders received in 2023
 - The acquisition of Tissue Converting increased Valmet's net working capital by approximately EUR 92 million in Q4/2023
 - Compared to year 2021, Valmet's net working capital has increased mainly in capital business and due to integration of Flow Control and Tissue Converting into Valmet
 - Today, Valmet's business mix contains more stable business, which typically ties up more net working capital than capital business
- Change in net working capital² EUR -180 million in 2023 and EUR -55 million in Q4/2023


Valmet implemented IFRS 16 – Leases as of January 1, 2019 by applying the simplified transition method and therefore 2018 figures are not restated.

1) Excluding business combinations and right-of-use assets.


2) Change in net working capital in the consolidated statement of cash flows.

Net debt and gearing increased compared with 2022

Net debt (EUR million) and gearing (%)



Net debt to EBITDA* ratio




- Gearing (40%) increased and net debt (EUR 1,027 million) increased compared with 2022
 - The increase in net debt and gearing in Q4/23 is mainly related to the acquisition of Tissue Converting business
 - The increase in net debt and gearing in Q2/22 is mainly related to the integration of Flow Control into Valmet
- Net debt to EBITDA* ratio increased compared with 2022
- The average interest rate of Valmet's total debt was 4.5% at the end of 2023
- Net financial expenses amounted to EUR 34 million in 2023 (EUR 5 million in 2022)

Valmet implemented IFRS 16 – Leases as of January 1, 2019 by applying the simplified transition method and therefore 2018 figures are not restated.

*Last twelve months (LTM) EBITDA


Capital employed, Comparable ROCE and EPS

Capital employed (EUR million) and Comparable return on capital employed (ROCE), before taxes (%)



- Integration of Flow Control into Valmet in Q2/2022 and the completion of the acquisition of Tissue Converting in Q4/2023 increased capital employed

Earnings per share (EPS) and Adjusted EPS, EUR



- Adjusted EPS decreased mainly due to higher net financial expenses and lower items affecting comparability


Valmet implemented IFRS 16 – Leases as of January 1, 2019 by applying the simplified transition method, and IFRS 15 – Revenue from Contracts with Customers as of January 1, 2018 by applying full retrospective method. Thus, figures presented are not fully comparable.

*Adjusted EPS. Adjusted earnings per share is an alternative performance measure that excludes the impact of fair value adjustments arising from business combinations, net of tax.



Dividend proposal, guidance and short-term market outlook

Dividend proposal



Dividend policy

- Dividend payout at least 50% of net profit

Board of Directors' dividend proposal to the Annual General Meeting

- EUR 1.35 dividend per share, which represents 70% payout ratio
- The dividend shall be paid in two installments

Guidance and short-term market outlook

Guidance for 2024

| | |
|-----------------|--|
| Guidance | <p>Valmet estimates that net sales in 2024 will remain at the previous year's level in comparison with 2023 (EUR 5,532 million) and Comparable EBITA in 2024 will remain at the previous year's level or increase in comparison with 2023 (EUR 619 million).</p> |
|-----------------|--|

Short-term market outlook

| | | Q1/2023 | Q2/2023 | Q3/2023 | Q4/2023 |
|------------------------|--------------------|---------------------|---------------------|---------------------|---------------------|
| Services | | Good | Good / Satisfactory | Good / Satisfactory | Good / Satisfactory |
| Automation | Flow Control | Good | Good | Good | Good |
| | Automation Systems | Good | Good | Good | Good |
| Pulp and Energy | Pulp | Good / Satisfactory | Satisfactory | Satisfactory | Satisfactory |
| | Energy | Good | Good | Good | Good |
| Paper | Board and Paper | Good | Satisfactory | Satisfactory | Satisfactory |
| | Tissue | Satisfactory | Satisfactory | Satisfactory | Satisfactory |

The short-term market outlook is based on customer activity (50%) and Valmet's capacity utilization (50%) and is given for the next six months following the reported quarter. The scale is 'weak-satisfactory-good'.

Q&A

Interim Review, January– March 2024

April 24, 2024

www.valmet.com/investors

Annual General Meeting 2024

March 21, 2024

www.valmet.com/investors

Important notice

IMPORTANT: The following applies to this document, the oral presentation of the information in this document by Valmet (the “Company”) or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation (collectively, the “Information”). In accessing the Information, you agree to be bound by the following terms and conditions.

The Information is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of, or located in, any locality, state, country or other jurisdiction where such distribution or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The Information is not for publication, release or distribution in the United States, the United Kingdom, Australia, Canada or Japan.

The Information does not constitute or form part of and should not be construed as an offer or the solicitation of an offer to subscribe for or purchase any securities, and nothing contained therein shall form the basis of or be relied on in connection with any contract or commitment whatsoever, nor does it constitute a recommendation regarding any securities. Prospective investors are required to make their own independent investigations and appraisals of the business and financial condition of the Company before taking any investment decision with respect to securities of the Company.

No securities of the Company are being offered or sold, directly or indirectly, in or into the United States and no shares in the Company have been, or will be, registered under the Securities Act of 1933, as amended (the “Securities Act”), or under the securities laws of any state of the United States and, accordingly, may not be offered or sold, directly or indirectly, in or into the United States (as defined in Regulation S under the Securities Act), unless registered under the Securities Act or pursuant to an exemption from the registration requirements of the Securities Act and in compliance with any applicable state securities laws of the United States.

The Information is directed solely at: (i) persons outside the United Kingdom, (ii) persons with professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 as amended (the “Order”), (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order and (iv) persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities of the Company or any member of its group may otherwise lawfully be communicated or caused to be communicated (all such persons in (i)-(iv) above being “Relevant Persons”). Any investment activity to which the Information relates will only be available to and will only be engaged with Relevant Persons. Any person who is not a Relevant Person should not act or rely on the Information. By accessing the Information, you represent that you are a Relevant Person.

The Information contains forward-looking statements. All statements other than statements of historical fact included in the Information are forward-looking statements. Forward-looking statements give the Company’s current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which it will operate in the future.

No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the Information or the opinions contained therein. The Information has not been independently verified and will not be updated. The Information, including but not limited to forward-looking statements, applies only as of the date of this document and is not intended to give any assurances as to future results. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to the Information, including any financial data or forward-looking statements, and will not publicly release any revisions it may make to the Information that may result from any change in the Company’s expectations, any change in events, conditions or circumstances on which these forward-looking statements are based, or other events or circumstances arising after the date of this document. Market data used in the Information not attributed to a specific source are estimates of the Company and have not been independently verified.

